GlassScriptPhysician profile
Anutida Charoentong
NPI 1013442904
$2,261.99
in general payments reported to CMS, 2019-2025
20 companies · $614 in 2025
The $614 reported for 2025 was more than what 77% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $30.60 · 2021: $14.62 · 2022: $445 · 2023: $558 · 2024: $600 · 2025: $614.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,772.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,771.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $559.65 | 2022-2025 | Vraylar, Qulipta, Linzess |
| Novo Nordisk INC | $470.50 | 2020-2025 | Wegovy |
| Lilly USA, LLC | $275.13 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Amgen INC. | $237.73 | 2020-2025 | Evenity, Prolia, Repatha |
| Pfizer INC. | $146.11 | 2022-2025 | |
| Glaxosmithkline, LLC. | $92.77 | 2022-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Exact Sciences Corporation | $68.46 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $61.71 | 2025 | Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $51.72 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $44.37 | 2024-2025 | Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.97 | 2023-2024 | Jardiance |
| Medtronic, INC. | $37.07 | 2022-2024 | Intellis Adaptivestim |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $35.68 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $32.27 | 2022-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $26.28 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $18.33 | 2025 | |
| Ibsa Pharma INC. | $18.07 | 2022 | |
| Paratek Pharmaceuticals, INC. | $17.13 | 2025 | Nuzyra |
| Inspire Medical Systems, INC. | $15.42 | 2025 | Inspire |
| Insmed, INC. | $14.62 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anutida Charoentong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.